18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management.
Harikrishna KommidiHua GuoFuad NuriliYogindra VedvyasMoonsoo M JinTimothy D McClureBehfar EhdaieHaluk B SaymanOguz AkinOmer ArasRichard TingPublished in: Journal of medicinal chemistry (2018)
[18/19F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [19F]-4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a <1 h, one-step, aqueous isotopic exchange reaction. [19F]-4 allows PSMA expression to be imaged by fluorescence (FL) and [18F]-PET. PC3-PIP (PSMA-positive, EC50 = 6.74 ± 1.33 nM) cancers are specifically delineated in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative) cells. Colocalization of [18/19F]-4 PET, fluorescence, scintillated biodistribution, and PSMA expression are observed.
Keyphrases
- pet ct
- pet imaging
- prostate cancer
- positron emission tomography
- poor prognosis
- radical prostatectomy
- randomized controlled trial
- quantum dots
- energy transfer
- single molecule
- induced apoptosis
- magnetic resonance
- computed tomography
- binding protein
- photodynamic therapy
- ionic liquid
- oxidative stress
- cell death
- young adults